

Milestone Achievements


- FDA removed clinical hold on CampETEC
- Initiation of IMM-124E Phase 2 CHIM clinical trial
- Board approves cGMP manufacture of IMM-529 and to proceed with pre-IND submission
- First cohort of 30 participants enrolled in Travelan Phase 2 clinical trial
- 40% of 868 participants enrolled in Travelan Phase 4 clinical trial

Paul Brennan appointed Non-Executive Chairman

Strong Sales Growth

Sales of Travelan® and Protectyn® increased by 136% in FY23 to AUD \$1.80 M, compared to AUD \$765 k in FY22. Sales would have been higher if not for waiting on TGA GMP Clearance. With clearance received, Immuron has recommenced sales in Australia with continued sales growth as international travel from Australia continues to rebound.

Research for Wholesale and Professional Investors



Provisional data for the most recent month has not had the full quality assurance methods applied as is done for the earlier months. Provisional estimates will be revised in the next issue of this publication.







FY24 Milestones

- Topline results for IMM-124E Phase 2 clinical trial
- Initiation of CampETEC Phase 2 clinical trial
- Topline results for CampETEC Phase 2
- Completion of in-patient phase of Travelan Phase 4 clinical trial
- Submission of pre-IND to US Food and Drug Administration (FDA) for IMM-529 (clostridioides difficile)

Military Health System Research Symposium

Immuron and our flagship product Travelan was recently showcased at #2023MHSRS to the 3000+ military medical professionals, researchers and U.S. Department of Defense leadership team @2023MHSRS


Abstract and Posters presented at this symposium can be found here:


https://www.immuron.com.au/product-science/

















Q&A with Steven Lydeamore



Creating New Products for Infectious Diseases



How Immuron's Gastrointestinal Health Immune Supplements Work



Substantial Sales Growth Driven by Resurgence in Travel



IMM-529 cGMP manufacturing and pre-IND submission to proceed



Innovation begins with collaboration